Current update on theranostic roles of cyclophilin A in kidney diseases
Issued Date
2022-01-01
Resource Type
eISSN
18387640
Scopus ID
2-s2.0-85131498832
Pubmed ID
35673572
Journal Title
Theranostics
Volume
12
Issue
9
Start Page
4067
End Page
4080
Rights Holder(s)
SCOPUS
Bibliographic Citation
Theranostics Vol.12 No.9 (2022) , 4067-4080
Suggested Citation
Hadpech S., Thongboonkerd V. Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics Vol.12 No.9 (2022) , 4067-4080. 4080. doi:10.7150/THNO.72948 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86895
Title
Current update on theranostic roles of cyclophilin A in kidney diseases
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Cyclophilin A (CyPA) or peptidylprolyl isomerase A (PPIA), an immunophilin with peptidyl-prolyl cis/trans isomerase (PPIase) activity, is an abundant cellular protein widely expressed across various cell types and tissues, including the kidney. Expression of CyPA in the kidney is relatively higher in proximal tubular epithelial cells than others along the nephron. Alterations in expression and secretion of CyPA play important roles in physiological processes and pathophysiology of several diseases affecting the kidney. Herein, we provide a brief overview of CyPA structural biology and present the current update on its theranostic roles in various kidney diseases, including diabetic nephropathy, acute kidney injury, chronic kidney disease, renal fibrosis, and nephrotoxicity associated with organ transplantation. Notably, the diagnostic/prognostic role for urinary CyPA in several of these kidney diseases is promising. Finally, future perspectives on the CyPA research, especially targeting CyPA for therapeutics, are discussed. A comprehensive understanding of the theranostic roles of CyPA in kidney diseases is expected to provide novel insights into the design of new therapeutic interventions and prevention strategies.